A PHASE 1/2A OPEN-LABEL DOSE-RANGING AND OBSERVER-BLIND PLACEBO-CONTROLLED, SAFETY AND IMMUNOGENICITY STUDY OF MRNA-1647 CYTOMEGALOVIRUS VACCINE IN FEMALE AND MALE PARTICIPANTS 9 TO 15 YEARS OF AGE AND PARTICIPANTS 16 TO 25 YEARS OF AGE

Registry ID

MRNA-1647-P104

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

MODERNATX, INC.

Start date

2023-04-19

Completion date

2026-05-12

Last update

2022-08-10

Conditions

• CYTOMEGALOVIRUS

Related clinical trials

• LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS IN PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION
• A PHASE 3, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF MRNA-1647 CYTOMEGALOVIRUS (CMV) VACCINE IN HEALTHY PARTICIPANTS 16 TO 40 YEARS OF AGE
• DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY AND IMMUNOGENICITY OF A 2-DOSE AND A 3-DOSE REGIMEN OF V160 (CYTOMEGALOVIRUS [CMV] VACCINE) IN HEALTHY SERONEGATIVE WOMEN, 16 TO 35 YEARS OF AGE
• A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF MARIBAVIR COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL TO EVALUATE THE PROECTIVE EFFICACY AND SAFETY OF A THERAPUTIC VACCINE, ASPO113, IN CYTOMEGALOVIRUS (CMV)- SEROPOSTIVIVE RECIPIENTS UNDERGOING ALLOGENIC, HEMATOPOIETIC CELL TRANSPLANT (HCT).

View on source registry